PDGFRB - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	CDK14	cyclin dependent kinase 14
Novel	CDX1	caudal type homeobox 1
Novel	CHRM3	cholinergic receptor muscarinic 3	Muscarinic acetylcholine receptors Acetylcholine regulates insulin secretion G alpha (q) signalling events	Cevimeline Tramadol Succinylcholine Trospium Ziprasidone Disopyramide Amitriptyline Ipratropium Olanzapine Metixene Terfenadine Clozapine Doxylamine Trihexyphenidyl Oxyphencyclimine Procyclidine Loxapine Carbamoylcholine Hyoscyamine Cyproheptadine Meperidine Imipramine Methscopolamine bromide Chlorpromazine Darifenacin Haloperidol Tridihexethyl Anisotropine methylbromide Nortriptyline Amoxapine Cinnarizine Atropine Thiopental Nicardipine Paroxetine Homatropine methylbromide Trimipramine Scopolamine Benzquinamide Propiomazine Tropicamide Brompheniramine Maprotiline Methantheline Glycopyrronium Bethanechol Tolterodine Oxybutynin Promethazine Pilocarpine Doxepin Desipramine Ketamine Quetiapine Mivacurium Diphenidol Aripiprazole Chlorprothixene Pancuronium Pipecuronium Methotrimeprazine Tiotropium Solifenacin Isopropamide Acetylcholine Arecoline Mepenzolate ALKS 27 Pizotifen Fesoterodine Methacholine Hexocyclium Aclidinium Umeclidinium Trimebutine Dosulepin Etoperidone Imidafenacin Butylscopolamine Homatropine Thonzylamine Revefenacin Propiverine Rociverine Diphemanil Aripiprazole lauroxil
Novel	FAXDC2	fatty acid hydroxylase domain containing 2
Novel	ITK	IL2 inducible T cell kinase	Generation of second messenger molecules FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization	Staurosporine Pazopanib Fostamatinib Zanubrutinib
Novel	MITF	melanocyte inducing transcription factor	SUMOylation of transcription factors		Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA) Waardenburg syndrome (WS) Malignant melanoma
Novel	PLAUR	plasminogen activator, urokinase receptor	Attachment of GPI anchor to uPAR Neutrophil degranulation Dissolution of Fibrin Clot	Alteplase Urokinase Tenecteplase WX-UK1 Lanoteplase
Novel	TUFM	Tu translation elongation factor, mitochondrial	Mitochondrial translation elongation	Zinc Guanosine-5'-Diphosphate Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Combined oxidative phosphorylation deficiency (COXPD)
	ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	Regulation of actin dynamics for phagocytic cup formation Role of ABL in ROBO-SLIT signaling Role of ABL in ROBO-SLIT signaling Myogenesis Myogenesis RHO GTPases Activate WASPs and WAVEs HDR through Single Strand Annealing (SSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Cyclin D associated events in G1 RUNX1 regulates transcription of genes involved in differentiation of HSCs RUNX2 regulates osteoblast differentiation FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	ATP Imatinib Dasatinib N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide Nilotinib XL228 Bosutinib 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA Myristic acid PD-166326 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide Regorafenib Ponatinib Fostamatinib Brigatinib Radotinib	Chronic myeloid leukemia (CML) Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
	ABL2	ABL proto-oncogene 2, non-receptor tyrosine kinase	Role of ABL in ROBO-SLIT signaling Role of ABL in ROBO-SLIT signaling Negative regulation of FLT3	ATP Dasatinib XL228 K-00546 Fostamatinib
	ARAF	A-Raf proto-oncogene, serine/threonine kinase	RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	ATP	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
	BAG1	BAG cochaperone 1	Regulation of HSF1-mediated heat shock response	(2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
	CAV1	caveolin 1	Triglyceride catabolism eNOS activation NOSTRIN mediated eNOS trafficking Basigin interactions Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Extra-nuclear estrogen signaling FOXO-mediated transcription of cell cycle genes		Congenital generalized lipodystrophy (CGL)
	CAV3	caveolin 3	Smooth Muscle Contraction Smooth Muscle Contraction		Caveolinopathies, including: Limb-girdle muscular dystrophy (LGMD) 1C; Rippling muscle disease (RMD); Idiopathic hyperCKemia; Distal myopathy with decreased caveolin 3; Hypertrophic cardiomyopathy (HCM) Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS) Limb-girdle muscular dystrophy (LGMD)
	CBL	Cbl proto-oncogene	Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Negative regulation of FLT3 FLT3 signaling by CBL mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
	CEP76	centrosomal protein 76	Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane AURKA Activation by TPX2
	COPA	COPI coat complex subunit alpha	COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic
	COPB1	COPI coat complex subunit beta 1	Neutrophil degranulation COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic
	CRK	CRK proto-oncogene, adaptor protein	ARMS-mediated activation ARMS-mediated activation Downstream signal transduction Regulation of actin dynamics for phagocytic cup formation p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 MET receptor recycling Regulation of signaling by CBL FCGR3A-mediated phagocytosis
	EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib	Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer

Search Results for: PDGFRB